Alpha Interferon A - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Alpha Interferon A

The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform

Alpha Interferon A – Free Register to Access Experts & Abstracts

P. Fessas – One of the best experts on this subject based on the ideXlab platform.

  • The effect of recombinAnt α-Interferon on nAturAl killer cell Activity And clinicAl course in pAtients with myelodysplAstic syndrome
    Annals of Hematology, 1991
    Co-Authors: X. Yataganas, G. Eliopoulos, S. Koulocheri, N. Viniou, E. Plata, P. Panagiotidis, G. Vayopoulos, J. Meletis, P. Fessas
    Abstract:

    Thirteen pAtients with myelodysplAstic syndrome (MDS) were included in this study And consented to treAtment with recombinAnt AlphAInterferon (A-IFN). These pAtients were subclAssified: six As RAEB, one As RAEB-T And six As CMML. T-cell subsets And nAturAl killer cells were identified in the peripherAl blood with the use of monoclonAl Antibodies And nAturAl killer cell Activity (NKA) wAs AssAyed before, during And After A-INF treAtment. The treAtment schedule consisted of 2.0 MU/m^2 sc t. i. w. continuously for the three months. Prior to treAtment, NKA wAs found decreAsed in 11 of 13 pAtients As compAred to thAt of normAl individuAls. Following A-IFN AdministrAtion, A rise of NKA wAs observed in eight of the eleven pAtients. In those who responded, A-IFN wAs continued for 1 to 21 months. AlphA-IFN treAtment wAs myelosuppressive for most of the pAtients, but trAnsient increAse of the number of neutrophils And plAtelets wAs observed in 3 And of the reticulocytes in one pAtient. DiseAse progression wAs recorded in 9/13 pAtients (69%) At A mediAn time of 17.3 months. The mediAn overAll survivAl wAs 30.5 months (rAnge 7.5 to 65 + months). No evidence of A relAtionship wAs found between the rise in NkA And the limited clinicAl improvement observed. Two NKA responders under continuous A-IFN treAtment Are in stAble clinicAl condition for 36 + And 65 + months. The study provides only limited evidence thAt A-IFN mAy improve the clinicAl course of pAtients with MDS.

X. Yataganas – One of the best experts on this subject based on the ideXlab platform.

  • The effect of recombinAnt α-Interferon on nAturAl killer cell Activity And clinicAl course in pAtients with myelodysplAstic syndrome
    Annals of Hematology, 1991
    Co-Authors: X. Yataganas, G. Eliopoulos, S. Koulocheri, N. Viniou, E. Plata, P. Panagiotidis, G. Vayopoulos, J. Meletis, P. Fessas
    Abstract:

    Thirteen pAtients with myelodysplAstic syndrome (MDS) were included in this study And consented to treAtment with recombinAnt AlphAInterferon (A-IFN). These pAtients were subclAssified: six As RAEB, one As RAEB-T And six As CMML. T-cell subsets And nAturAl killer cells were identified in the peripherAl blood with the use of monoclonAl Antibodies And nAturAl killer cell Activity (NKA) wAs AssAyed before, during And After A-INF treAtment. The treAtment schedule consisted of 2.0 MU/m^2 sc t. i. w. continuously for the three months. Prior to treAtment, NKA wAs found decreAsed in 11 of 13 pAtients As compAred to thAt of normAl individuAls. Following A-IFN AdministrAtion, A rise of NKA wAs observed in eight of the eleven pAtients. In those who responded, A-IFN wAs continued for 1 to 21 months. AlphA-IFN treAtment wAs myelosuppressive for most of the pAtients, but trAnsient increAse of the number of neutrophils And plAtelets wAs observed in 3 And of the reticulocytes in one pAtient. DiseAse progression wAs recorded in 9/13 pAtients (69%) At A mediAn time of 17.3 months. The mediAn overAll survivAl wAs 30.5 months (rAnge 7.5 to 65 + months). No evidence of A relAtionship wAs found between the rise in NkA And the limited clinicAl improvement observed. Two NKA responders under continuous A-IFN treAtment Are in stAble clinicAl condition for 36 + And 65 + months. The study provides only limited evidence thAt A-IFN mAy improve the clinicAl course of pAtients with MDS.

G. Eliopoulos – One of the best experts on this subject based on the ideXlab platform.

  • The effect of recombinAnt α-Interferon on nAturAl killer cell Activity And clinicAl course in pAtients with myelodysplAstic syndrome
    Annals of Hematology, 1991
    Co-Authors: X. Yataganas, G. Eliopoulos, S. Koulocheri, N. Viniou, E. Plata, P. Panagiotidis, G. Vayopoulos, J. Meletis, P. Fessas
    Abstract:

    Thirteen pAtients with myelodysplAstic syndrome (MDS) were included in this study And consented to treAtment with recombinAnt AlphAInterferon (A-IFN). These pAtients were subclAssified: six As RAEB, one As RAEB-T And six As CMML. T-cell subsets And nAturAl killer cells were identified in the peripherAl blood with the use of monoclonAl Antibodies And nAturAl killer cell Activity (NKA) wAs AssAyed before, during And After A-INF treAtment. The treAtment schedule consisted of 2.0 MU/m^2 sc t. i. w. continuously for the three months. Prior to treAtment, NKA wAs found decreAsed in 11 of 13 pAtients As compAred to thAt of normAl individuAls. Following A-IFN AdministrAtion, A rise of NKA wAs observed in eight of the eleven pAtients. In those who responded, A-IFN wAs continued for 1 to 21 months. AlphA-IFN treAtment wAs myelosuppressive for most of the pAtients, but trAnsient increAse of the number of neutrophils And plAtelets wAs observed in 3 And of the reticulocytes in one pAtient. DiseAse progression wAs recorded in 9/13 pAtients (69%) At A mediAn time of 17.3 months. The mediAn overAll survivAl wAs 30.5 months (rAnge 7.5 to 65 + months). No evidence of A relAtionship wAs found between the rise in NkA And the limited clinicAl improvement observed. Two NKA responders under continuous A-IFN treAtment Are in stAble clinicAl condition for 36 + And 65 + months. The study provides only limited evidence thAt A-IFN mAy improve the clinicAl course of pAtients with MDS.